{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:16:36Z","timestamp":1761765396690},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2011,4,6]],"date-time":"2011-04-06T00:00:00Z","timestamp":1302048000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1007\/s10120-011-0043-3","type":"journal-article","created":{"date-parts":[[2011,4,5]],"date-time":"2011-04-05T02:04:54Z","timestamp":1301969094000},"page":"332-338","source":"Crossref","is-referenced-by-count":8,"title":["Phase II study of weekly paclitaxel, cisplatin, and 5-fluorouracil for advanced gastric cancer"],"prefix":"10.1007","volume":"14","author":[{"given":"Takuo","family":"Hara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuaki","family":"Sakatoku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Oba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Omura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,4,6]]},"reference":[{"key":"43_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","volume":"55","author":"DM Parkin","year":"2005","unstructured":"Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74\u2013108.","journal-title":"CA Cancer J Clin"},{"key":"43_CR2","unstructured":"Statistics and Information Department, Minister\u2019s Secretariat, Ministry of Health, Labor and Welfare. Vital statistics of Japan 2006. Tokyo: Health and Welfare Statistics Association; 2008."},{"key":"43_CR3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P","volume":"72","author":"AM Murad","year":"1993","unstructured":"Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 1993;72:37\u201341.","journal-title":"Cancer"},{"key":"43_CR4","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/bjc.1995.114","volume":"71","author":"S Pyrh\u00f6nen","year":"1995","unstructured":"Pyrh\u00f6nen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995;71:587\u201391.","journal-title":"Br J Cancer"},{"key":"43_CR5","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1023\/A:1008243606668","volume":"8","author":"B Glimelius","year":"1997","unstructured":"Glimelius B, Ekstr\u00f6m K, Hoffman K, Graf W, Sj\u00f6d\u00e9n PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997;8:163\u20138.","journal-title":"Ann Oncol"},{"key":"43_CR6","first-page":"269","volume":"4","author":"JA Ajani","year":"1998","unstructured":"Ajani JA, Fairweather J, Dumas P, Patt YZ, Pazdur R, Mansfield PF. Phase II study of taxol in patients with advanced gastric carcinoma. Cancer J Sci Am. 1998;4:269\u201374.","journal-title":"Cancer J Sci Am"},{"key":"43_CR7","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/00001813-199804000-00003","volume":"9","author":"S Cascinu","year":"1998","unstructured":"Cascinu S, Graziano F, Cardarelli N, Marcellini M, Giordani P, Menichetti ET, et al. Phase II study of paclitaxel in pretreated advanced gastric cancer. Anticancer Drugs. 1998;9:307\u201310.","journal-title":"Anticancer Drugs"},{"key":"43_CR8","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s00595-008-3769-8","volume":"38","author":"Y Emi","year":"2008","unstructured":"Emi Y, Yamamoto M, Takahashi I, Orita H, Kakeji Y, Kohnoe S, et al. Phase II study of weekly paclitaxel by one-hour infusion for advanced gastric cancer. Surg Today. 2008;38:1013\u201320.","journal-title":"Surg Today"},{"key":"43_CR9","first-page":"2667","volume":"27","author":"Y Kodera","year":"2007","unstructured":"Kodera Y, Ito S, Mochizuki Y, Fujitake S, Koshikawa K, Kanyama Y, et al. A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer (CCOG0302 study). Anticancer Res. 2007;27:2667\u201371.","journal-title":"Anticancer Res"},{"key":"43_CR10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s10120-005-0351-6","volume":"9","author":"S Hironaka","year":"2006","unstructured":"Hironaka S, Zenda S, Boku N, Fukutomi A, Yoshino T, Onozawa Y. Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer. 2006;9:14\u20138.","journal-title":"Gastric Cancer"},{"key":"43_CR11","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s10120-009-0524-9","volume":"12","author":"R Shimoyama","year":"2009","unstructured":"Shimoyama R, Yasui H, Boku N, Onozawa Y, Hironaka S, Fukutomi A, et al. Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin. Gastric Cancer. 2009;12:206\u201311.","journal-title":"Gastric Cancer"},{"key":"43_CR12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s10120-009-0505-z","volume":"12","author":"J Sakamoto","year":"2009","unstructured":"Sakamoto J, Matsui T, Kodera Y. Paclitaxel chemotherapy for the treatment of gastric cancer. Gastric Cancer. 2009;12:69\u201378.","journal-title":"Gastric Cancer"},{"key":"43_CR13","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1179\/joc.2007.19.4.444","volume":"19","author":"M Ninomiya","year":"2007","unstructured":"Ninomiya M, Kondo K, Matsuo K, Hirabayashi N, Kojima H, Kobayashi M, et al. Multicenter phase II trial of combination chemotherapy with weekly paclitaxel and 5-fluorouracil for the treatment of advanced or recurrent gastric carcinoma. J Chemother. 2007;19:444\u201350.","journal-title":"J Chemother"},{"key":"43_CR14","first-page":"1905","volume":"52","author":"N Nagata","year":"2005","unstructured":"Nagata N, Kobayashi M, Kojima H, Kondo K, Hirabayashi N, Matsui T, et al. Phase I study of paclitaxel and cisplatin for patients with advanced or recurrent gastric cancer. Hepatogastroenterology. 2005;52:1905\u201310.","journal-title":"Hepatogastroenterology"},{"key":"43_CR15","first-page":"1846","volume":"55","author":"N Nagata","year":"2008","unstructured":"Nagata N, Kimura M, Hirabayashi N, Tuburaya A, Murata T, Kondo K, et al. Phase II study of weekly paclitaxel and cisplatin combination therapy for advanced or recurrent gastric cancer. Hepatogastroenterology. 2008;55:1846\u201350.","journal-title":"Hepatogastroenterology"},{"key":"43_CR16","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00280-006-0305-7","volume":"59","author":"T Hara","year":"2007","unstructured":"Hara T, Omura K, Hirano M, Asada Y, Munemoto Y, Sakamoto J. A phase I study of paclitaxel, cisplatin, and fluorouracil (TCF) for advanced gastric cancer. Cancer Chemother Pharmacol. 2007;59:631\u20136.","journal-title":"Cancer Chemother Pharmacol"},{"key":"43_CR17","doi-asserted-by":"publisher","first-page":"5660","DOI":"10.1200\/JCO.2005.17.376","volume":"23","author":"JA Ajani","year":"2005","unstructured":"Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Cabral Filho S, et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol. 2005;23:5660\u20137.","journal-title":"J Clin Oncol"},{"key":"43_CR18","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/oxfordjournals.annonc.a057858","volume":"2","author":"AJ Lacave","year":"1991","unstructured":"Lacave AJ, Bar\u00f3n FJ, Ant\u00f3n LM, Estrada E, De Sande LM, Palacio I, et al. Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: a phase II trial. Ann Oncol. 1991;2:751\u20134.","journal-title":"Ann Oncol"},{"key":"43_CR19","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S0959-8049(97)86090-X","volume":"15","author":"A Webb","year":"1997","unstructured":"Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997;15:261\u20137.","journal-title":"J Clin Oncol"},{"key":"43_CR20","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","volume":"24","author":"E Cutsem Van","year":"2006","unstructured":"Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991\u20137.","journal-title":"J Clin Oncol"},{"key":"43_CR21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa073149","volume":"358","author":"D Cunningham","year":"2008","unstructured":"Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36\u201346.","journal-title":"N Engl J Med"},{"key":"43_CR22","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/S1470-2045(09)70259-1","volume":"10","author":"N Boku","year":"2009","unstructured":"Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009;10:1063\u20139.","journal-title":"Lancet Oncol"},{"key":"43_CR23","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1056\/NEJMoa072252","volume":"357","author":"S Sakuramoto","year":"2007","unstructured":"Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810\u201320.","journal-title":"N Engl J Med"},{"key":"43_CR24","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","volume":"9","author":"W Koizumi","year":"2008","unstructured":"Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215\u201321.","journal-title":"Lancet Oncol"},{"key":"43_CR25","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1093\/jjco\/hyn096","volume":"38","author":"K Shitara","year":"2008","unstructured":"Shitara K, Muro K, Ura T, Takahari D, Yokota T, Sawaki A, et al. Chemotherapy for gastric cancer that recurs after adjuvant chemotherapy with S-1. Jpn J Clin Oncol. 2008;38:786\u20139.","journal-title":"Jpn J Clin Oncol"},{"key":"43_CR26","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/00001813-200206000-00008","volume":"13","author":"F Honecker","year":"2002","unstructured":"Honecker F, Kollmannsberger C, Quietzsch D, Haag C, Schroeder M, Spott C, et al. Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer. Anticancer Drugs. 2002;13:497\u2013503.","journal-title":"Anticancer Drugs"},{"key":"43_CR27","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.biopha.2008.08.018","volume":"63","author":"Y Gu","year":"2009","unstructured":"Gu Y, Shu Y, Xu Q. A study of weekly paclitaxel plus 5-fluorouracil and cisplatin for patients with advanced or recurrent inoperable gastric cancer. Biomed Pharmacother. 2009;63:293\u20136.","journal-title":"Biomed Pharmacother"},{"key":"43_CR28","doi-asserted-by":"publisher","first-page":"586","DOI":"10.3346\/jkms.2008.23.4.586","volume":"23","author":"J Hwang","year":"2008","unstructured":"Hwang J, Cho SH, Shim HJ, Lee SR, Ahn JS, Yang DH, et al. Phase II study of paclitaxel, cisplatin, and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer. J Korean Med Sci. 2008;23:586\u201391.","journal-title":"J Korean Med Sci"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-011-0043-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10120-011-0043-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-011-0043-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-011-0043-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,9]],"date-time":"2019-06-09T17:36:08Z","timestamp":1560101768000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10120-011-0043-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,6]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["43"],"URL":"https:\/\/doi.org\/10.1007\/s10120-011-0043-3","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,6]]}}}